Barclays PLC Acadia Pharmaceuticals Inc Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 248,448 shares of ACAD stock, worth $6.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
248,448
Previous 298,445
16.75%
Holding current value
$6.11 Million
Previous $5.48 Million
24.67%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding ACAD
# of Institutions
355Shares Held
163MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$1.05 Billion8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$374 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$297 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$210 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$172 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.98B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...